WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell®
Wearable Pain Relief Technology™ is available in Canada via
Amazon Canada.
"Canadian consumers have been asking for easier access to Quell,"
said Frank McGillin, SVP and General Manager of NeuroMetrix. "This is an
important step as we look to expand availability of our patented, 100%
drug free technology for the relief of widespread chronic pain."
Canadian consumers can now purchase Quell locally on Amazon.ca.
About Quell
Quell is FDA cleared and designed for millions of people suffering from
chronic pain. The advanced wearable device is lightweight and can be
worn during the day while active, and at night while sleeping. It has
been cleared by the FDA for treatment of chronic pain without a
prescription. In a recent study, 81% of Quell users reported an
improvement in their chronic pain. Quell gives users the option to
start, stop, and adjust therapy discreetly via their smartphone. It also
enables advanced sleep tracking that provides feedback on eight
dimensions of sleep including sleep duration, quality, body position,
time out of bed, and repetitive leg movements throughout the night.
Quell is available at select healthcare professionals and retailers. To
find a Quell retailer near you, visit the Store
Locator at QuellRelief.com.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160614006290/en/
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
